CORDIS
EU research results

CORDIS

English EN
Transfer of multivirus-specific T-cells following transplantation

Transfer of multivirus-specific T-cells following transplantation

Objective

Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV), Epstein-Barr-virus (EBV) and Adenovirus (AdV) are major unsolved problems for patients receiving allogeneic HSCT. Refractory viral infections post-HSCT are rare, life-threatening conditions due to the deficient T-cell response post-SCT and lacking effective treatment options. Protective T-cell immunity could be restored by means of a procedure known as adoptive T-cell transfer. Although cellular immunotherapy is considered a major recent breakthrough in medicine, none of the cellular treatment approaches has yet become a standard treatment. The reason for this limited translation into daily clinical practice is the lack of controlled, prospective clinical trials investigating efficacy of immunotherapy. The objective of TRACE is to bring adoptive T-cell transfer into clinical routine as a life-saving, curative and safe treatment for refractory viral infection post-HSCT. TRACE is a multi-national clinical trial to prove efficacy and safety of adoptive T-cell transfer in immune-compromized individuals. For the first time, this trial will show that a unique individualized immunotherapy could be included into evidence based clinical routine in rare diseases. Regulatory and structural hurdles will be overcome by standardized GMP-procedures. It will be a major milestone in the development of medicine and health economics to bring such a unique personalized treatment approach into a clinical efficacy trial. The consortium provide excellence in immunotherapy through partners from basic, clinical and industrial research and GMP facilities, with proven qualification and expertise in the field of HSCT, GMP manufacturing and adoptive T-cell transfer. It will bring medicine towards physiological self-protection of the human body instead of cost-intensive toxic agents and will thereby improve survival and quality of life.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Address

Geschwister Scholl Platz 1
80539 Muenchen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 641 600

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 207 925

OSPEDALE PEDIATRICO BAMBINO GESU

Italy

EU Contribution

€ 442 025

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 350 600

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY

France

EU Contribution

€ 507 570

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 349 725

Universitair Ziekenhuis Gent

Belgium

EU Contribution

€ 401 550

ORION CLINICAL SERVICES LTD

United Kingdom

EU Contribution

€ 2 099 005

Project information

Grant agreement ID: 755005

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 000 000

  • EU contribution

    € 6 000 000

Coordinated by:

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany